On
- Decrease in operational costs, which will free up funds for additional capital reserves and investments;
- Larger public float, which will encourage higher trading volume;
- Consolidated brand identity, resulting in more effective marketing strategy;
- Easier access for new investments and investors, as there will be no confusion whether to invest in NKPH or NIKA;
- Easier preparation of financial statements, audits and other disclosures
Detailed merger information can be found via NKPH’s published disclosures on www.sec.gov.
About
Forward-looking Statement:
This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward- looking statements.” These forward-looking statements generally are identified by the words “believes,” “expects,” “anticipates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
CONTACTClifford Redekop , Corporate SecretaryCOMPANY Nika Pharmaceuticals, Inc. PHONE (702)-326-3615 EMAIL info@nikapharmaceuticals.com WEB www.nikapharmaceuticals.com
Source:
2024 GlobeNewswire, Inc., source